Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 7/20 | 0.71 |
| ▸ | GSK3B | P49841 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339365 | 0.85 | GSK3A (0.73) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL20339366 | 0.84 | GSK3A (0.71) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL1520611 | 0.83 | GSK3A (1.00) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL6692164 | 0.83 | GSK3A (0.70) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL20339824 | 0.83 | GSK3A (0.66) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL20339372 | 0.83 | GSK3A (1.00) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL20339339 | 0.83 | GSK3A (0.62) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL20339310 | 0.82 | GSK3A (0.68) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL2908429 | 0.80 | GSK3A (0.66) | GSK3AGSK3BALDH1A1KMT2AGAA | |
| SCHEMBL6793399 | 0.80 | ALDH1A1 (1.00) | GSK3AGSK3BALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | GSK3A 2436/4885GSK3B 2077/4885ALDH1A1 1070/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | GSK3A 2452/4885GSK3B 2517/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.